US Patent Issued to Guangzhou Innocare Pharma Tech on Oct. 21 for "Heterocyclic compounds for mediating tyrosine kinase 2 activity" (Chinese Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,448,382, issued on Oct. 21, was assigned to Guangzhou Innocare Pharma Tech Co. Ltd. (Guangzhou, China).

"Heterocyclic compounds for mediating tyrosine kinase 2 activity" was invented by Xiangyang Chen (Beijing) and Yucheng Pang (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "Heterocyclic compounds shown in Formula (I) suitable for inhibiting or regulating the activity of Janus kinase (JAK), particularly tyrosine kinase 2 (TYK2). The compounds are useful for preventing and/or treating relevant JAK-mediated diseases, such as autoimmune diseases, inflammatory diseases, and cancers."

The patent was filed on Dec. 22, 2021, under Application No. 17/5...